Teza Capital Management LLC Sells 5,532 Shares of Zoetis Inc. (NYSE:ZTS)

Teza Capital Management LLC lowered its position in Zoetis Inc. (NYSE:ZTS – Get Rating) by 74.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,904 shares of the company’s stock after selling 5,532 shares during the period. Teza Capital Management LLC’s holdings in Zoetis were worth $282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in ZTS. Oakworth Capital Inc. boosted its holdings in shares of Zoetis by 33.7% in the third quarter. Oakworth Capital Inc. now owns 270 shares of the company’s stock valued at $40,000 after purchasing an additional 68 shares during the period. Vantage Consulting Group Inc boosted its holdings in shares of Zoetis by 4.6% in the third quarter. Vantage Consulting Group Inc now owns 1,559 shares of the company’s stock valued at $231,000 after purchasing an additional 68 shares during the period. My Legacy Advisors LLC boosted its holdings in shares of Zoetis by 1.6% in the third quarter. My Legacy Advisors LLC now owns 4,471 shares of the company’s stock valued at $650,000 after purchasing an additional 70 shares during the period. Enterprise Financial Services Corp boosted its holdings in shares of Zoetis by 2.9% in the third quarter. Enterprise Financial Services Corp now owns 2,521 shares of the company’s stock valued at $374,000 after purchasing an additional 70 shares during the period. Finally, Peloton Wealth Strategists boosted its holdings in shares of Zoetis by 0.8% in the third quarter. Peloton Wealth Strategists now owns 8,610 shares of the company’s stock valued at $1,277,000 after purchasing an additional 70 shares during the period. Institutional investors own 90.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZTS. Barclays boosted their price target on Zoetis from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Tuesday, February 21st. Morgan Stanley lowered their price target on Zoetis from $264.00 to $248.00 and set an “overweight” rating for the company in a report on Tuesday, November 15th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $223.83.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $161.53 on Monday. The company has a market capitalization of $74.85 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 2.50 and a beta of 0.76. Zoetis Inc. has a 52 week low of $124.15 and a 52 week high of $201.32. The company has a quick ratio of 1.63, a current ratio of 2.37 and a debt-to-equity ratio of 1.49. The firm has a 50 day moving average of $163.51 and a 200 day moving average of $155.06.

Zoetis (NYSE:ZTS – Get Rating) last issued its quarterly earnings data on Tuesday, February 14th. The company reported $1.15 EPS for the quarter, hitting analysts’ consensus estimates of $1.15. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zoetis had a net margin of 26.16% and a return on equity of 50.20%. Zoetis’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.00 earnings per share. On average, sell-side analysts predict that Zoetis Inc. will post 5.39 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 1st. Stockholders of record on Friday, April 21st will be given a dividend of $0.375 per share. This represents a $1.50 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date of this dividend is Thursday, April 20th. Zoetis’s payout ratio is presently 33.33%.

Zoetis Profile

(Get Rating)

Zoetis, Inc engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S.